 | • レポートコード：MRC2302F0096 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、236ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査レポートでは、2021年に480.9億ドルであった世界の創薬市場規模が、2022年に547.4億ドルになり、2027年まで年平均14.00%で成長して1055.9億ドルまで拡大すると予測しています。本レポートは、創薬の世界市場について調査し、市場の動向を明らかにした資料であり、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、薬剤別（生物学的製剤、低分子製剤）分析、技術別（コンビナトリアルケミストリー、ハイスループットスクリーニング、ナノテクノロジー、ファーマコゲノミクス）分析、エンドユーザー別（医薬品開発業務受託機関（CRO）、製薬会社）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報など以下の構成でまとめています。また、Abbott Laboratories Inc.、Affymetrix Inc.、Agilent Technologies Inc.、Albany Molecular Research Inc.、Arqule Inc.、Astrazeneca Plc.、Bio-Rad Laboratories Inc.、Caliper Life Sciences Inc.などの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の創薬市場規模：薬剤別 - 生物学的製剤の市場規模 - 低分子製剤の市場規模 ・世界の創薬市場規模：技術別 - コンビナトリアルケミストリーにおける市場規模 - ハイスループットスクリーニングにおける市場規模 - ナノテクノロジーにおける市場規模 - ファーマコゲノミクスにおける市場規模 ・世界の創薬市場規模：エンドユーザー別 - 医薬品開発業務受託機関（CRO）における市場規模 - 製薬会社における市場規模 ・世界の創薬市場規模：地域別 - 南北アメリカの創薬市場規模 アメリカの創薬市場規模 カナダの創薬市場規模 ブラジルの創薬市場規模 … - アジア太平洋の創薬市場規模 日本の創薬市場規模 中国の創薬市場規模 インドの創薬市場規模 韓国の創薬市場規模 台湾の創薬市場規模 … - ヨーロッパ/中東/アフリカの創薬市場規模 イギリスの創薬市場規模 ドイツの創薬市場規模 フランスの創薬市場規模 ロシアの創薬市場規模 … - その他地域の創薬市場規模 ・競争状況 ・企業情報 |
The Global Drug Discovery Market size was estimated at USD 48.09 billion in 2021 and expected to reach USD 54.74 billion in 2022, and is projected to grow at a CAGR 14.00% to reach USD 105.59 billion by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Drug Discovery to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Drug Type, the market was studied across Biologic Drugs and Small Molecule Drugs.
Based on Technology, the market was studied across Combinatorial Chemistry, High Throughput Screening, Nanotechnology, and Pharmacogenomics.
Based on End User, the market was studied across Contract Research Organizations (CROs) and Pharmaceutical Companies.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Drug Discovery market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Drug Discovery Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Drug Discovery Market, including Abbott Laboratories Inc., Affymetrix Inc., Agilent Technologies Inc., Albany Molecular Research Inc., Arqule Inc., Astrazeneca Plc., Bio-Rad Laboratories Inc., Caliper Life Sciences Inc., Celera Corp, Charles River Laboratories International Inc., Chembridge Corp, EVOTEC AG, F. Hoffmann-La Roche Ltd., Gyros AB, Incyte Corp, Life Technologies Corp, Perkinelmer Inc., Shimadzu Corp, Sigma-Aldrich Corp, Tecan Group Ltd., and Thermo Fisher Scientific Inc..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Drug Discovery Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Drug Discovery Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Drug Discovery Market?
4. What is the competitive strategic window for opportunities in the Global Drug Discovery Market?
5. What are the technology trends and regulatory frameworks in the Global Drug Discovery Market?
6. What is the market share of the leading vendors in the Global Drug Discovery Market?
7. What modes and strategic moves are considered suitable for entering the Global Drug Discovery Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising R&D expenditure in the pharmaceutical & biopharmaceutical industry
5.1.1.2. Increasing need for outsourcing analytical testing and clinical trial services
5.1.1.3. Initiatives for investigation on rare diseases and orphan drugs
5.1.1.4. Focus on drug discovery
5.1.2. Restraints
5.1.2.1. High cost of drug discovery and development
5.1.2.2. Stringent regulations governing drug discovery and animal usage
5.1.3. Opportunities
5.1.3.1. Growth in the biologics market
5.1.3.2. Patent expiries
5.1.3.3. Emerging markets
5.1.4. Challenges
5.1.4.1. Long duration for market entry of a drug
5.2. Cumulative Impact of COVID-19
6. Drug Discovery Market, by Drug Type
6.1. Introduction
6.2. Biologic Drugs
6.3. Small Molecule Drugs
7. Drug Discovery Market, by Technology
7.1. Introduction
7.2. Combinatorial Chemistry
7.3. High Throughput Screening
7.4. Nanotechnology
7.5. Pharmacogenomics
8. Drug Discovery Market, by End User
8.1. Introduction
8.2. Contract Research Organizations (CROs)
8.3. Pharmaceutical Companies
9. Americas Drug Discovery Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Drug Discovery Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Drug Discovery Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. Abbott Laboratories Inc.
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Affymetrix Inc.
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Agilent Technologies Inc.
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Albany Molecular Research Inc.
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Arqule Inc.
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Astrazeneca Plc.
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Bio-Rad Laboratories Inc.
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Caliper Life Sciences Inc.
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Celera Corp
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Charles River Laboratories International Inc.
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Chembridge Corp
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. EVOTEC AG
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. F. Hoffmann-La Roche Ltd.
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. Gyros AB
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Incyte Corp
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Life Technologies Corp
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. Perkinelmer Inc.
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Shimadzu Corp
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Sigma-Aldrich Corp
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. Tecan Group Ltd.
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
13.21. Thermo Fisher Scientific Inc.
13.21.1. Business Overview
13.21.2. Key Executives
13.21.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing